Cardiogenic shock - Beyond the large infarction

Critical Care Medicine

Volumn 34, Issue 8, 2006, Pages 2234-2235

  Cotter, Gad ^a   Berger, Peter B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INOTROPIC AGENT; INTERLEUKIN 6; NITRIC OXIDE SYNTHASE INHIBITOR; TILARGININE ACETATE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE; VASOCONSTRICTOR AGENT;

AORTA BALLOON; CARDIOGENIC SHOCK; CLINICAL TRIAL; EDITORIAL; ENZYME INHIBITION; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REVASCULARIZATION; HEART OUTPUT; HUMAN; MOLECULAR DYNAMICS; MORTALITY; MYOCARDITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; VASCULAR RESISTANCE; BLOOD; DRUG ANTAGONISM; NOTE;

ENZYME INHIBITORS; HUMANS; INTERLEUKIN-6; NITRIC OXIDE SYNTHASE; SHOCK, CARDIOGENIC; VASOCONSTRICTOR AGENTS;

EID: 33748117803     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000229671.12922.27     Document Type: Editorial

References (12)

1. Hochman JS, Sleeper LA, Webb JG, et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625-634
2. Thiele H, Sick P, Boudriot E, et al: Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26:1276-1283
3. Chen EW, Canto JG, Parsons LS, et al: Investigators in the National Registry of Myocardial Infarction 2. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 2003; 26:951-957
4. Babaev A, Frederick PD, Pasta DJ, et al: NRMI Investigators: Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294:448-454
5. Dauerman HL, Goldberg RJ, White K, et al: Global Registry of Acute Coronary Events. GRACE Investigators. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002; 90:838-842
6. Hochman JS: Cardiogenic shock complicating acute myocardial infarction. Expanding the paradigm. Circulation 2002; 107:2998-3002
7. Geppert A, Dorninger A, Delle-Karth G, et al: Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2006; 34:2035-2042
8. Tarantini G, Ramondo A, Isabella G, et al: Pressure response to vasopressors and mortality after direct angioplasty for cardiogenic shock. Int J Cardiol 2004; 94:197-202
9. Smith HJ, Oriol A, Morch J, et al: Hemodynamic studies in cardiogenic shock. Treatment with isoproteranol and metaramiol. Circulation 1967; 35:1084-1091
10. Cotter G, Kaluski E, Blatt A, et al: L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101:1358-1361
11. Cotter G, Kaluski E, Milo O, et al: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003; 24:1287-1295
12. Holmes DR Jr, Hasdai D, White J, et al: Long-term outcome of patients with cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2004; 43(Suppl A):274A